Clinical Trials
77 trials68Ga-DOTATATE Neuroblastoma Imaging Pilot
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
National Cancer Institute (NCI)
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
National Institutes of Health Clinical Center (CC)
SABRE
Children's National Research Institute
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
MK-9999-01A
Merck Sharp & Dohme LLC
MRG003
Sun Yat-sen University
Pediatric Long-Term Follow-up and Rollover Study
Novartis
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Stanford University
Phase II Study of Proton Radiation Therapy for Neuroblastoma
Massachusetts General Hospital
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
Indocyanine Green (ICG) Guided Tumor Resection
St. Jude Children's Research Hospital
PEDS-PLAN
Milton S. Hershey Medical Center
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Milton S. Hershey Medical Center
NYMC195
New York Medical College
ANTARES
Instituto do Cancer do Estado de São Paulo
PEEL-224
Children's Hospital of Philadelphia
LUPARPED
Fundación de investigación HM
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Milton S. Hershey Medical Center
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Milton S. Hershey Medical Center
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Memorial Sloan Kettering Cancer Center
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Memorial Sloan Kettering Cancer Center
DUAL-NK-NB
Beijing Biotech
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
UNC Lineberger Comprehensive Cancer Center
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
National Institutes of Health Clinical Center (CC)
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
New Approaches to Neuroblastoma Therapy Consortium
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
University of Florida
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
C17 Council
A Study of Avutometinib for People With Solid Tumor Cancers
Memorial Sloan Kettering Cancer Center
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Y-mAbs Therapeutics
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Memorial Sloan Kettering Cancer Center
RISE in HR NBL
Dana-Farber Cancer Institute
GLOW-FISH
Princess Maxima Center for Pediatric Oncology
18F-DOPA II - PET Imaging Optimization
University of Alberta
SPEARHEAD-3 Pediatric Study
USWM, LLC (dba US WorldMeds)
IMMUNEORGANOID
Gustave Roussy, Cancer Campus, Grand Paris
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II,Multi-center, Clinical Study.
Sun Yat-sen University
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Milton S. Hershey Medical Center
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Milton S. Hershey Medical Center
NB-NK-2026
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
NMTT
Milton S. Hershey Medical Center
BEACON2
University of Birmingham
GPC2
Children's Hospital of Philadelphia
Aflac-NBL-2002
Emory University
Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
Boston Children's Hospital
PHOX2B
Children's Hospital of Philadelphia